2 Billion Reasons to Love CRISPR Therapeutics Right Now
Key Points
CRISPR Therapeutics is still losing money, but it has an expanding pipeline.
The biotech is seeing growing sales from its one product, Casgevy.
It also has other promising drug candidates in its pipeline.
- 10 stocks we like better than CRISPR Therapeutics ›
CRISPR Therapeutics (NASDAQ: CRSP) is a pioneering biotech company, but it isn't yet a profitable one. That's why its shares are down slightly so far this year.
There are plenty of reasons, though, to be bullish on the stock, not the least of which is its improved cash position. The company had nearly $2 billion in cash, cash equivalents, and marketable securities at the end of 2025.
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
Image source: Getty Images.
That kind of cushion gives the company breathing room to ramp up sales of its only approved gene-editing therapy, Casgevy, which is used as a one-time treatment for sickle cell disease and transfusion-dependent beta thalassemia. Casgevy, priced at $2.2 million per treatment, had $116 million in 2025 sales, including $54 million in the fourth quarter alone, indicating its sales are accelerating. Still, the company lost $578.6 million last year.
Casgevy is just the start
CRISPR gene-editing has the potential to cure patients of disease, not just treat them. Casgevy has already shown it can be a functional cure. The problem, for now, is that Casgevy is very expensive and treats only a small portion of the population.
However, CRISPR already has five other therapies in clinical trials in its pipeline, including those with much larger markets. The biotech company's strong cash position gives it time to bring some of these therapies through the approval process.
The three with the broadest promise are CXT310 and CXT320 for cardiovascular disease and CTX112 for various cancers and autoimmune disorders. CTX310 and CTX320 are "in vivo" gene-editing treatments, meaning they are designed to edit genes directly in the body. Both therapies aim to reduce the risk of heart disease by lowering blood lipids in the liver.
CTX112, more commonly known as zugo-cel (short for zugocaptagene geleucel), is CRISPR Therapeutics' next-generation "off-the-shelf" (allogeneic) CAR T-cell therapy. It is being tested on autoimmune disorders such as lupus and systemic sclerosis, two rare diseases, but it is also seen as a potential therapy to treat B-cell cancers, the most common type of blood cancers in the U.S.
Should you buy stock in CRISPR Therapeutics right now?
Before you buy stock in CRISPR Therapeutics, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and CRISPR Therapeutics wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $555,526!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,156,403!*
Now, it’s worth noting Stock Advisor’s total average return is 968% — a market-crushing outperformance compared to 191% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of April 13, 2026.
James Halley has positions in CRISPR Therapeutics. The Motley Fool has positions in and recommends CRISPR Therapeutics. The Motley Fool has a disclosure policy.
Recommended Articles
